• Je něco špatně v tomto záznamu ?

Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices

DJ. Goldstein, B. Meyns, R. Xie, J. Cowger, S. Pettit, T. Nakatani, I. Netuka, S. Shaw, M. Yanase, JK. Kirklin,

. 2019 ; 38 (4) : 352-363. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025898

BACKGROUND: The IMACS Registry compiles and analyzes worldwide data from patients undergoing implantation of durable left ventricular assist devices. METHODS: Data encompassing 16,286 LVAD recipients from 4 collectives and 24 individual hospitals was collected and analyzed. In this 3rd annual report we compare and contrast outcomes, adverse events and risks factors between axial flow and centrifugal flow device recipients. RESULTS: Significant differences were found in the baseline characteristics of axial vs centrifugal flow LVAD recipients. Survival was similar between pump types. INTERMACS profile 1-3 constitute 85% of implants. A survival gap persists in destination therapy compared to bridge patients. RVAD need and delay impact survival dramatically. Centrifugal flow outperforms axial flow recipients in regards to GI bleeding and freedom from hemocompatibility related adverse events. No significant difference in the actuarial freedom from all strokes or either stroke subtype (hemorrhagic or ischemic) was seen among the two types of pumps. New end points to guide decision making are proposed. CONCLUSIONS: We demonstrate a transition from axial to centrifugal flow with four-year survival that approximates 60%. A high frequency of adverse events remains an impediment to the wider adoption of these technologies. In the future, composite study endpoints examining life quality and adverse events beyond survival may help in shared decision making prior to MCS implant, and may provide the requisite data to support extension of MCS therapy into the lesser ill heart failure population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025898
003      
CZ-PrNML
005      
20201222155528.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.healun.2019.02.004 $2 doi
035    __
$a (PubMed)30945637
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Goldstein, Daniel J $u Montefiore Medical Center, Bronx, New York, USA. Electronic address: dgoldste@montefiore.org.
245    10
$a Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices / $c DJ. Goldstein, B. Meyns, R. Xie, J. Cowger, S. Pettit, T. Nakatani, I. Netuka, S. Shaw, M. Yanase, JK. Kirklin,
520    9_
$a BACKGROUND: The IMACS Registry compiles and analyzes worldwide data from patients undergoing implantation of durable left ventricular assist devices. METHODS: Data encompassing 16,286 LVAD recipients from 4 collectives and 24 individual hospitals was collected and analyzed. In this 3rd annual report we compare and contrast outcomes, adverse events and risks factors between axial flow and centrifugal flow device recipients. RESULTS: Significant differences were found in the baseline characteristics of axial vs centrifugal flow LVAD recipients. Survival was similar between pump types. INTERMACS profile 1-3 constitute 85% of implants. A survival gap persists in destination therapy compared to bridge patients. RVAD need and delay impact survival dramatically. Centrifugal flow outperforms axial flow recipients in regards to GI bleeding and freedom from hemocompatibility related adverse events. No significant difference in the actuarial freedom from all strokes or either stroke subtype (hemorrhagic or ischemic) was seen among the two types of pumps. New end points to guide decision making are proposed. CONCLUSIONS: We demonstrate a transition from axial to centrifugal flow with four-year survival that approximates 60%. A high frequency of adverse events remains an impediment to the wider adoption of these technologies. In the future, composite study endpoints examining life quality and adverse events beyond survival may help in shared decision making prior to MCS implant, and may provide the requisite data to support extension of MCS therapy into the lesser ill heart failure population.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a výroční zprávy jako téma $7 D000847
650    _2
$a asistovaná cirkulace $7 D001243
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x chirurgie $7 D006333
650    12
$a podpůrné srdeční systémy $7 D006353
650    _2
$a transplantace srdce a plic $7 D016041
650    _2
$a lidé $7 D006801
650    _2
$a mezinárodní spolupráce $7 D007391
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a protézy - design $7 D011474
650    _2
$a registrace $7 D012042
650    _2
$a společnosti lékařské $7 D012955
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Meyns, Bart $u University Hospitals Leuven, Leuven, Belgium.
700    1_
$a Xie, Rongbing $u University of Alabama at Birmingham, Birmingham, Alabama, USA.
700    1_
$a Cowger, Jennifer $u Henry Ford Hospital, Detroit, Michigan, USA.
700    1_
$a Pettit, Stephen $u Royal Papworth Hospital, Papworth Everard, UK.
700    1_
$a Nakatani, Takeshi $u Maki Hospital, Osaka, Japan.
700    1_
$a Netuka, Ivan $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Shaw, Steven $u Wythenshawe Hospital, Manchester, UK.
700    1_
$a Yanase, Masanobu $u National Cardiovascular Center, Suita, Japan.
700    1_
$a Kirklin, James K $u University of Alabama at Birmingham, Birmingham, Alabama, USA.
773    0_
$w MED00002704 $t The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation $x 1557-3117 $g Roč. 38, č. 4 (2019), s. 352-363
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30945637 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155523 $b ABA008
999    __
$a ok $b bmc $g 1600043 $s 1116584
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 38 $c 4 $d 352-363 $e - $i 1557-3117 $m The Journal of heart and lung transplantation $n J Heart Lung Transplant $x MED00002704
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace